Table 4

Prevention of New-Onset AF by Bucindolol in BEST by Genotype, Total Number of Events, and Norepinephrine Change at 3 Months in Patients in Genetic Groups

Measure1389Arg/Arg + any α2C) (P = 206, B = 235)1389Gly Carrier + any α2C) (P = 254, B = 230)1 Gly carrier + α2c Wt/Wt) (P = 183, B = 175)1 Gly carrier + α2c Del) (P = 71, B = 55)
HR (95% CI), no. of events, p value0.26 (0.12 to 0.57)
36 events, p = 0.0003
1.01 (0.56 to 1.84)
44 events, p = 0.97
0.94 (0.48 to 1.82)
36 events, p = 0.84
1.33 (0.32 to 5.64)
8 events, p = 0.70
NE change at 3 months (pg/ml)P = 14 ± 20 B = 71 ± 22 p = 0.0013P = 31 ± 22 B = 78 ± 24 p = 0.0019P = 38 ± 25 B = 54 ± 22 p = 0.0039P = 7 ± 45 B = 164 ± 79 p = 0.23

Data show prevention of new-onset atrial fibrillation (AF) by bucindolol in BEST by genotype (hazard ratio [R], 95% confidence interval [CI]), total number of events, and p value. Norepinephrine (NE) change at 3 months in patients in genetic groups.

B = bucindolol; Del = deletion; P = placebo; Wt = wild type; other abbreviations as in Table 1.

  • Member of 3-group construct tested for interaction.